Tvardi Therapeutics (NASDAQ:TVRD) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Tvardi Therapeutics (NASDAQ:TVRD) announced its quarterly earnings results on Friday. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.03, FiscalAI reports.

Tvardi Therapeutics Trading Up 2.2%

Shares of NASDAQ:TVRD traded up $0.03 on Friday, reaching $1.18. 74,674 shares of the company’s stock were exchanged, compared to its average volume of 763,004. Tvardi Therapeutics has a twelve month low of $0.77 and a twelve month high of $5.69. The company has a fifty day moving average of $1.25 and a 200-day moving average of $2.61. The company has a market capitalization of $15.74 million, a price-to-earnings ratio of -0.42 and a beta of 0.37.

Institutional Investors Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of TVRD. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at $63,000. BlackRock Inc. bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $181,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $34,000. Institutional investors own 44.66% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TVRD shares. BTIG Research decreased their price objective on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Lucid Cap Mkts upgraded Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, October 2nd. Wall Street Zen downgraded Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, November 1st. Finally, Chardan Capital initiated coverage on Tvardi Therapeutics in a research note on Tuesday, October 20th. They issued a “buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.40.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development. The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.